Clinical trial
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT05379985
Study timeline
Study start (actual)2022-05-31Date precision: day
Registry last updated2026-05-15
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Non-small Cell Lung Cancer (NSCLC)unresolved
Colorectal Cancer (CRC)unresolved
Pancreatic Ductal Adenocarcinoma (PDAC)unresolved
Advanced Solid Tumorsunresolved
Interventions
RMC-6236DRUG
Sponsors & collaborators
Revolution Medicines, Inc.lead sponsor
Mapped research locations
New YorkNew York, United States3HoustonTexas, United States1BostonMassachusetts, United States1DallasTexas, United States1BaltimoreMaryland, United States1AtlantaGeorgia, United States1San AntonioTexas, United States1NashvilleTennessee, United States1SeattleWashington, United States1CincinnatiOhio, United States1TampaFlorida, United States1AustinTexas, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05379985 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.